Skip to content

The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction

The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction: the TITAN-MRI Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05751057
Acronym
TITAN-MRI
Enrollment
120
Registered
2023-03-02
Start date
2022-12-14
Completion date
2024-12-31
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST Elevation Myocardial Infarction (NSTEMI)

Keywords

cardiovascular magnetic resonance, Myocardial Infaction, Invasive Coronary Angiography

Brief summary

The goal of this prospective study is to evaluate the role of cardiovascular magnetic resonance (CMR) in patients with suspected non-ST elevation myocardial infarction (NSTEMI). The main endpoint is the reclassification rate, defined as the number of patients in whom the information provided by pre-angiography CMR affects the revascularization strategy or the final diagnosis. Participants will undergo to CMR before invasive coronary angiography (ICA).

Detailed description

All patients with NSTEMI eligible for the study undergo CMR prior to ICA. To avoid any delay in patients' treatment all examination will be analyzed by local trained staff at each center. All patients will thereafter undergo ICA and the standard of care (SOC) decision-making on revascularization strategy and diagnosis will be declared by the treating physician, which will be blinded to the participation of the patients in the study and about CMR results. The treating physician will also declare patient's next management according to ICA results. After having declared the diagnosis, the treating physician will then be informed about the CMR findings. Therefore, according to CMR results the treating physician may eventually modify the initial diagnosis and management. Treatment plan modifications include difference in the identification of the culprit lesion, referring the patient to medical therapy instead of a revascularization procedure or viceversa, switching from a percutaneous to a surgical revascularization procedure or viceversa, or need for further cardiac or non-cardiac investigations. Initial diagnosis includes confirmed NSTEMI or all other possible alternative diagnosis and proposed additional diagnostic examination(s) for further differential diagnosis. The CMR-modified SOC (CMR-SOC) and diagnosis made considering CMR results will be collected.

Interventions

All NSTEMI patients will undergo to CMR before invasive coronary intervention.

Sponsors

Cardiocentro Ticino
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years old * Presence of criteria for acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction: * Signs and symptoms of myocardial ischemia * Detection of acute myocardial injury defined as a rise and/or fall of high-sensitivity cardiac Troponin (hs-cTn) values with at least one value above the 99th percentile Upper Reference Limit at baseline or after presentation. * Patients scheduled for ICA. * Written informed consent.

Exclusion criteria

* Patients diagnosed with myocardial infarction with ST segment elevation. * Very High-risk NSTEMI patients according to 2020 ESC Guidelines on Acute Coronary Syndromes: * Haemodynamic instability * Cardiogenic shock * Recurrent/refractory chest pain despite medical treatment * Life-threatening arrhythmias * Mechanical complications of MI * Acute heart failure clearly related to NSTEMI * ST-segment depression\>1mm/6 leads plus ST-segment elevation aVR and/or V1. * Legally incompetent to provide informed consent * Participation in another clinical study. * Regular known contraindications to CMR at time of inclusion such as: * Severe renal impairment (eGFR \< 30 ml / min / 1,73 m2) or on dialysis treatment * Claustrophobia * Known pregnancy or breast-feeding patients * Non MR compatible devices * Known allergy to Gadolinium

Design outcomes

Primary

MeasureTime frameDescription
Reclassification rateimmediately after invasive coronary angiographynumber of patients in whom the information provided by CMR affects the final diagnosis

Secondary

MeasureTime frameDescription
Culprit lesion identificationduring invasive coronary angiographyability of CMR to detect culprit lesion
Revascularization strategyimmediately after invasive coronary angiographynumber of patients in whom CMR affects the revascularization strtegy

Countries

Switzerland

Contacts

Primary ContactAnna Giulia Pavon, MD
annagiulia.pavon@eoc.ch0041 091 811 5371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026